As a veteran analyst of the biopharmaceutical landscape, Ivan Kairatov has spent years navigating the complex intersection of clinical innovation and market dynamics. With a background rooted in deep research and development, Kairatov has become a prominent voice advocating for a paradigm shift in how the industry approaches women’s health. He joins us today to discuss the persistent gaps in menopause research, the commercialization of unproven treatments, and the structural hurdles that have prevented the development of a unified therapeutic solution for the millions of women navigating this transition.
The following discussion explores the financial disparities stalling drug development, the rise of the $17 billion commercial menopause market, and the promise of new non-hormonal therapies. Kairatov also shares his vision for a personalized approach to women’s health that mirrors the precision of modern oncology.
Only about 6% of private healthcare funding is currently directed toward women’s health. How does this specific investment gap stall the development of new medications, and what structural changes are necessary to ensure women are more accurately represented in clinical research?
The stark reality is that when only 6% of private capital flows into women’s health, innovation becomes a slow-motion process rather than a revolution. This funding gap creates a vicious cycle where a lack of early-stage investment leads to a limited pipeline, which in turn makes the sector look “risky” to larger pharmaceutical companies looking for a return on investment. To break this, we need to fundamentally change how we design the infrastructure of research to accommodate the lives of the participants. For instance, women often carry the dual burden of professional work and domestic caretaking, so we must make trials more convenient and accessible to ensure they aren’t excluded by the sheer weight of their schedules. Without these structural shifts, doctors will remain hamstrung by a limited evidence base, forced to make critical treatment decisions based on data that doesn’t fully represent the female experience.
Many women are spending significant sums on expensive hormone panel testing and unproven supplements that lack clinical validation. What are the primary risks of using these commercial products over evidence-based treatments, and how can patients better identify which solutions are actually backed by rigorous science?
The rise of the $17 billion menopause market has unfortunately opened the door for products that prioritize profit over proven efficacy. We see many women spending hundreds of dollars on hormone panel tests that major medical societies, such as the American College of Obstetricians and Gynecologists, consider unnecessary because there is no defined clinical window for such testing. The danger here is that these tests are often used to justify “custom” hormone regimens that haven’t been vetted for safety or long-term outcomes, pulling patients away from evidence-based practices. Patients need to be wary of anecdotal evidence found on blogs or social media and instead look for treatments that have cleared the rigorous FDA approval process. When a product skips the R&D investment phase, it usually means the patient is the one taking the risk, rather than the manufacturer.
With roughly 6,000 women reaching menopause every day, the experience varies wildly from debilitating hot flashes to cognitive “brain fog.” Why has it been so difficult for pharmaceutical companies to create a single blockbuster treatment, and what metrics should be used to measure success in such a diverse patient population?
The difficulty lies in the sheer heterogeneity of the condition; menopause isn’t a singular disease state but a diverse constellation of symptoms that hit 6,000 women daily in unique ways. For one woman, the primary struggle is vasomotor symptoms like night sweats, while for another, it’s a total loss of cognitive clarity often described as “brain fog.” Pharmaceutical companies typically look for a single “blockbuster” indication to justify the high costs of development, but in menopause, there is no one-size-fits-all drug that can address every symptom simultaneously. We need to shift our metrics of success from “total symptom elimination” to more targeted outcomes that reflect individual quality-of-life improvements. Success should be measured by how effectively a drug hits a specific pathway, such as the NK3 receptors for hot flashes, rather than expecting one pill to solve a multifaceted physiological transition.
New non-hormonal drugs targeting specific receptors are now entering a market that has been cautious since the safety concerns of the early 2000s. How do these new options compare to traditional hormone replacement therapy in terms of efficacy, and what hurdles do they face regarding insurance reimbursement and patient access?
We are seeing a fascinating shift with new non-hormonal entries like Astellas’ Veozah and Bayer’s recently approved Lynkuet, which target NK1 and NK3 receptors specifically to manage hot flashes. These drugs offer a vital alternative for women who cannot or choose not to use traditional hormone replacement therapy, especially given the lingering fears from the 2002 Women’s Health Initiative study. However, the path to market dominance is steep; for example, Veozah has faced slower sales due to reimbursement complications and a recent safety warning regarding liver complications. Even with Bayer projecting sales of over $1 billion for Lynkuet, the real hurdle remains insurance coverage. If these innovative, non-hormonal options are not accessible or affordable, many women will remain stuck with older therapies or, worse, no treatment at all.
There is a growing call to treat menopause with a personalized approach similar to specialized cancer therapies. How can researchers better connect the dots between hormonal shifts and interrelated conditions like Alzheimer’s or autoimmune diseases, and what practical steps would make participating in clinical trials easier for busy women?
The future of this field lies in treating women’s health with the same sophistication we apply to CAR-T or personalized oncology, where the solution is tailored to the individual’s specific biological profile. We know that menopause is linked to broader health issues like Alzheimer’s and autoimmune diseases, which disproportionately affect women, yet we haven’t fully mapped these connections in a way that informs clinical practice. To get there, we must lower the barriers to entry for clinical trials by making them “decentralized” or more integrated into a woman’s daily routine. If we can’t make trial participation convenient for a woman who is juggling a career and caregiving for both children and elderly parents, we will never gather the high-quality data needed to understand these complex hormonal links. It’s about meeting women where they are, rather than expecting them to find time they don’t have.
What is your forecast for the menopause treatment landscape over the next decade?
I believe we are on the cusp of a significant transition where the “shadows” around menopause finally dissipate, leading to a much more robust biotech pipeline. Over the next ten years, I expect to see more targeted, non-hormonal therapies enter the market as companies like AbCellera progress through phase 2 trials, offering more nuanced choices beyond the traditional HRT vs. nothing binary. We will likely see a push toward higher clinical standards that will eventually squeeze out the unproven supplement market, as 80% of women who currently suffer in silence begin to demand evidence-based care from their physicians. Ultimately, as smaller biotechs prove the ROI in this space, the larger “Big Pharma” players will follow suit, leading to a decade where personalized, data-driven menopause management becomes the global standard of care.
